{"id":"NCT00510146","sponsor":"Eli Lilly and Company","briefTitle":"Olanzapine Treatment of Patients With Bipolar I Disorder","officialTitle":"Efficacy and Safety of Olanzapine in the Treatment of Patients With Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison With Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2010-03","completion":"2010-07","firstPosted":"2007-08-01","resultsPosted":"2011-05-26","lastUpdate":"2011-05-26"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression, Bipolar"],"interventions":[{"type":"DRUG","name":"Olanzapine","otherNames":["LY170053","Zyprexa"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Olanzapine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Olanzapine (open-label treatment period)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.","primaryOutcome":{"measure":"Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)","timeFrame":"Baseline, Endpoint (Week 6)","effectByArm":[{"arm":"Olanzapine","deltaMin":29.36,"sd":5.71},{"arm":"Placebo","deltaMin":28.69,"sd":6.33}],"pValues":[{"comp":"OG000 vs OG001","p":"0.018"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":16,"countries":["China","Japan","South Korea"]},"refs":{"pmids":["24417745","23672672","22918966"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":343},"commonTop":["Weight increased","Somnolence","Increased appetite","Nasopharyngitis","Sedation"]}}